Pedia Loss
This article was originally published in The Tan Sheet
Executive Summary
Feb. 4 congressional letter to pediatric appetite suppressant marketer Dynamic Health Products marks expansion of House Energy & Commerce/Oversight & Investigations Subcommittee inquiry into dietary supplements aimed at children. Letter from Chairman James Greenwood (R-Penn.) follows previous correspondence. Greenwood notes the company previously said Pedia Loss is no longer publicly available, yet the product is still offered on the firm's 1website. Greenwood requests DHP provide records on development, marketing and any adverse events. The subcommittee previously targeted Skinny Pill for Kids. A separate investigation by the subcommittee into ephedra culminated in high-profile hearings which reignited the debate on the adequacy of protections under DSHEA (2"The Tan Sheet" July 28, 2003, p. 5)...
You may also be interested in...
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.